33451357|t|Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study.
33451357|a|BACKGROUND: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-beta (Abeta) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD. METHODS: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of Abeta (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period. Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers. RESULTS: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with Abeta accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO). Rates of tau accumulation among carriers were most rapid in parietal neocortex (~ 9%/year). EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers. CONCLUSIONS: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between Abeta burden and neocortical tau accumulation in ADAD.
33451357	13	20	amyloid	Disease	MESH:C000718787
33451357	25	28	tau	Gene	4137
33451357	45	83	autosomal dominant Alzheimer's disease	Disease	MESH:D000544
33451357	181	219	autosomal dominant Alzheimer's disease	Disease	MESH:D000544
33451357	221	225	ADAD	Disease	MESH:D000544
33451357	283	295	amyloid-beta	Gene	351
33451357	297	302	Abeta	Gene	351
33451357	308	311	tau	Gene	4137
33451357	404	407	tau	Gene	4137
33451357	572	576	ADAD	Disease	MESH:D000544
33451357	596	600	ADAD	Disease	MESH:D000544
33451357	620	632	Presenilin-1	Gene	5663
33451357	633	638	E280A	ProteinMutation	tmVar:p|SUB|E|280|A;HGVS:p.E280A;VariantGroup:0;CorrespondingGene:5663;RS#:63750231;CorrespondingSpecies:9606;CA#:341491
33451357	725	730	Abeta	Gene	351
33451357	732	757	11C-Pittsburgh compound B	Chemical	-
33451357	763	766	tau	Gene	4137
33451357	768	784	18F-flortaucipir	Chemical	MESH:C000591008
33451357	1177	1181	ADAD	Disease	MESH:D000544
33451357	1213	1218	Abeta	Gene	351
33451357	1316	1319	tau	Gene	4137
33451357	1341	1344	tau	Gene	4137
33451357	1354	1373	hippocampal atrophy	Disease	MESH:D001284
33451357	1387	1404	cognitive decline	Disease	MESH:D003072
33451357	1423	1426	tau	Gene	4137
33451357	1509	1512	tau	Gene	4137
33451357	1590	1593	tau	Gene	4137
33451357	1611	1628	cognitive decline	Disease	MESH:D003072
33451357	1729	1733	ADAD	Disease	MESH:D000544
33451357	1804	1807	tau	Gene	4137
33451357	1859	1864	Abeta	Gene	351
33451357	1888	1891	tau	Gene	4137
33451357	1908	1912	ADAD	Disease	MESH:D000544
33451357	Association	MESH:D000544	RS#:63750231;HGVS:p.E280A;CorrespondingGene:5663
33451357	Association	MESH:D003072	4137
33451357	Association	MESH:D000544	4137
33451357	Association	MESH:D000544	351
33451357	Association	MESH:D000544	5663
33451357	Association	MESH:D000544	5663

